semaglutide oral cardiovascular indication news 2025 FDA approves for reducing risks in adults with type 2 diabetes Oral Semaglutide Lowers Cardiovascular Risk

Example letter contents included the text: Compounded drug products are not FDA-approved

Cagrilintide Cagrilintide is an investigational amylin receptor agonist developed for the treatment of obesity and weight management

Stopping suddenly can lead to a return of symptoms

Per below & follow-up guidance from Highmark Pennsylvania Account Management There are NO rebates within the Small Group entities for 2023 MLR rebate year Communications surrounding Individual & Large Group issuances will begin next week (see chart of delivery timelines below) If carrier notification is received related to specific Large Market Clients qualifying to be issued an MLR rebate, we will share with you and your teams

Eating every 2-3 hours becomes especially important to prevent blood sugar fluctuations

If youve tried unsuccessfully to lose weight through diet and exercise alone, Semaglutide may be a good option to help you take charge of your health